Louis P. Lacasse
Presidente presso Centre For Commercialization of Cancer Immunotherapy
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Lambert Busque | M | - |
Centre For Commercialization of Cancer Immunotherapy
 Centre For Commercialization of Cancer Immunotherapy Centre For Commercialization of Cancer Immunotherapy provides solution for the development, translation, and commercialization of cancer immunotherapy and regenerative medicine. It offers clinical research unit, contract research organization, and innovation and commercialization unit services. The company was founded by Lambert Busque, Denis-Claude Roy and is headquartered in Montréal, Canada. | - |
| Claude Vezeau | M | - |
Bellus Health (Innodia), Inc.
 Bellus Health (Innodia), Inc. Pharmaceuticals: MajorHealth Technology Bellus Health (Innodia), Inc. manufactures biopharmaceutical products for the treatment and prevention of amyloidosis, metabolic syndrome, and diabetics related diseases. The company was founded in 2002 and is headquartered in Laval, Canada. | 22 anni |
| Inès Holzbaur | M | - |
GeneChem Management, Inc.
 GeneChem Management, Inc. Investment ManagersFinance GeneChem Management Inc (GeneChem) is an independent venture capital firm founded in 1997. The firm is headquartered in Montréal.
AgeChem Financial, Inc.
 AgeChem Financial, Inc. Financial ConglomeratesFinance AgeChem Financial, Inc. engages in the provision of investment services, It seeks to invest in companies developing therapeutics targeting age-related diseases. The company was founded in 2006 and is headquartered in Montreal, Canada.
Aegera Therapeutics, Inc.
 Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | 25 anni |
| Freda Miller | M | - |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | 24 anni |
| Martial Lacroix | M | - |
GeneChem Management, Inc.
GeneChem Management, Inc. Investment ManagersFinance GeneChem Management Inc (GeneChem) is an independent venture capital firm founded in 1997. The firm is headquartered in Montréal.
AgeChem Financial, Inc.
AgeChem Financial, Inc. Financial ConglomeratesFinance AgeChem Financial, Inc. engages in the provision of investment services, It seeks to invest in companies developing therapeutics targeting age-related diseases. The company was founded in 2006 and is headquartered in Montreal, Canada. | 27 anni |
| Hélène Dufourd | F | - |
The Caisse de dépôt et placement du Québec
 The Caisse de dépôt et placement du Québec Investment ManagersFinance The Caisse de dépôt et placement du Québec (CDPQ) is a government-owned institutional fund manager headquartered in Montréal, Canada. Founded in 1965, CDPQ manages the funds of several depositor groups primarily for public and parapublic pension and insurance plans which pay out benefits to more than two million Quebecers each year. | 29 anni |
| Perry B. Molinoff | M | 84 |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | - |
| Alex MacKenzie | M | - |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | 24 anni |
| Robert Korneluk | M | - |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | 24 anni |
| Elizabeth Douville | M | - |
GeneChem Management, Inc.
GeneChem Management, Inc. Investment ManagersFinance GeneChem Management Inc (GeneChem) is an independent venture capital firm founded in 1997. The firm is headquartered in Montréal.
AgeChem Financial, Inc.
AgeChem Financial, Inc. Financial ConglomeratesFinance AgeChem Financial, Inc. engages in the provision of investment services, It seeks to invest in companies developing therapeutics targeting age-related diseases. The company was founded in 2006 and is headquartered in Montreal, Canada. | 27 anni |
| Benoît Deschamps | M | 72 |
Centre For Commercialization of Cancer Immunotherapy
Centre For Commercialization of Cancer Immunotherapy Centre For Commercialization of Cancer Immunotherapy provides solution for the development, translation, and commercialization of cancer immunotherapy and regenerative medicine. It offers clinical research unit, contract research organization, and innovation and commercialization unit services. The company was founded by Lambert Busque, Denis-Claude Roy and is headquartered in Montréal, Canada.
The Caisse de dépôt et placement du Québec
The Caisse de dépôt et placement du Québec Investment ManagersFinance The Caisse de dépôt et placement du Québec (CDPQ) is a government-owned institutional fund manager headquartered in Montréal, Canada. Founded in 1965, CDPQ manages the funds of several depositor groups primarily for public and parapublic pension and insurance plans which pay out benefits to more than two million Quebecers each year. | 6 anni |
| Denis Roy | M | - |
Centre For Commercialization of Cancer Immunotherapy
Centre For Commercialization of Cancer Immunotherapy Centre For Commercialization of Cancer Immunotherapy provides solution for the development, translation, and commercialization of cancer immunotherapy and regenerative medicine. It offers clinical research unit, contract research organization, and innovation and commercialization unit services. The company was founded by Lambert Busque, Denis-Claude Roy and is headquartered in Montréal, Canada. | - |
| Steven Mayer | M | - |
Bellus Health (Innodia), Inc.
Bellus Health (Innodia), Inc. Pharmaceuticals: MajorHealth Technology Bellus Health (Innodia), Inc. manufactures biopharmaceutical products for the treatment and prevention of amyloidosis, metabolic syndrome, and diabetics related diseases. The company was founded in 2002 and is headquartered in Laval, Canada. | - |
| Kathryn Hayashi | F | - |
Centre For Commercialization of Cancer Immunotherapy
Centre For Commercialization of Cancer Immunotherapy Centre For Commercialization of Cancer Immunotherapy provides solution for the development, translation, and commercialization of cancer immunotherapy and regenerative medicine. It offers clinical research unit, contract research organization, and innovation and commercialization unit services. The company was founded by Lambert Busque, Denis-Claude Roy and is headquartered in Montréal, Canada. | - |
| Isabelle Riviere | M | - |
Centre For Commercialization of Cancer Immunotherapy
Centre For Commercialization of Cancer Immunotherapy Centre For Commercialization of Cancer Immunotherapy provides solution for the development, translation, and commercialization of cancer immunotherapy and regenerative medicine. It offers clinical research unit, contract research organization, and innovation and commercialization unit services. The company was founded by Lambert Busque, Denis-Claude Roy and is headquartered in Montréal, Canada. | - |
| Amal Khouri | F | - |
Centre For Commercialization of Cancer Immunotherapy
Centre For Commercialization of Cancer Immunotherapy Centre For Commercialization of Cancer Immunotherapy provides solution for the development, translation, and commercialization of cancer immunotherapy and regenerative medicine. It offers clinical research unit, contract research organization, and innovation and commercialization unit services. The company was founded by Lambert Busque, Denis-Claude Roy and is headquartered in Montréal, Canada. | - |
| Bernard Massie | M | - |
Centre For Commercialization of Cancer Immunotherapy
Centre For Commercialization of Cancer Immunotherapy Centre For Commercialization of Cancer Immunotherapy provides solution for the development, translation, and commercialization of cancer immunotherapy and regenerative medicine. It offers clinical research unit, contract research organization, and innovation and commercialization unit services. The company was founded by Lambert Busque, Denis-Claude Roy and is headquartered in Montréal, Canada. | - |
| Janet Dancey | M | - |
Centre For Commercialization of Cancer Immunotherapy
Centre For Commercialization of Cancer Immunotherapy Centre For Commercialization of Cancer Immunotherapy provides solution for the development, translation, and commercialization of cancer immunotherapy and regenerative medicine. It offers clinical research unit, contract research organization, and innovation and commercialization unit services. The company was founded by Lambert Busque, Denis-Claude Roy and is headquartered in Montréal, Canada. | - |
| Thomas Tradler | M | - |
Centre For Commercialization of Cancer Immunotherapy
Centre For Commercialization of Cancer Immunotherapy Centre For Commercialization of Cancer Immunotherapy provides solution for the development, translation, and commercialization of cancer immunotherapy and regenerative medicine. It offers clinical research unit, contract research organization, and innovation and commercialization unit services. The company was founded by Lambert Busque, Denis-Claude Roy and is headquartered in Montréal, Canada. | - |
| Timothy Smith | M | - |
Centre For Commercialization of Cancer Immunotherapy
Centre For Commercialization of Cancer Immunotherapy Centre For Commercialization of Cancer Immunotherapy provides solution for the development, translation, and commercialization of cancer immunotherapy and regenerative medicine. It offers clinical research unit, contract research organization, and innovation and commercialization unit services. The company was founded by Lambert Busque, Denis-Claude Roy and is headquartered in Montréal, Canada. | - |
| Shona McDiarmid | M | - |
Bellus Health (Innodia), Inc.
Bellus Health (Innodia), Inc. Pharmaceuticals: MajorHealth Technology Bellus Health (Innodia), Inc. manufactures biopharmaceutical products for the treatment and prevention of amyloidosis, metabolic syndrome, and diabetics related diseases. The company was founded in 2002 and is headquartered in Laval, Canada. | - |
| Francesco Bellini | M | 77 |
Bellus Health (Innodia), Inc.
Bellus Health (Innodia), Inc. Pharmaceuticals: MajorHealth Technology Bellus Health (Innodia), Inc. manufactures biopharmaceutical products for the treatment and prevention of amyloidosis, metabolic syndrome, and diabetics related diseases. The company was founded in 2002 and is headquartered in Laval, Canada. | - |
| Michael B. Cross | M | 59 |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | - |
| Michel Saucier | M | - |
Bellus Health (Innodia), Inc.
Bellus Health (Innodia), Inc. Pharmaceuticals: MajorHealth Technology Bellus Health (Innodia), Inc. manufactures biopharmaceutical products for the treatment and prevention of amyloidosis, metabolic syndrome, and diabetics related diseases. The company was founded in 2002 and is headquartered in Laval, Canada. | - |
| Lennie Ryer | M | 64 |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | - |
| Denis Garceau | M | 67 |
Bellus Health (Innodia), Inc.
Bellus Health (Innodia), Inc. Pharmaceuticals: MajorHealth Technology Bellus Health (Innodia), Inc. manufactures biopharmaceutical products for the treatment and prevention of amyloidosis, metabolic syndrome, and diabetics related diseases. The company was founded in 2002 and is headquartered in Laval, Canada. | - |
| Yves Bonhomme | M | - |
Bellus Health (Innodia), Inc.
Bellus Health (Innodia), Inc. Pharmaceuticals: MajorHealth Technology Bellus Health (Innodia), Inc. manufactures biopharmaceutical products for the treatment and prevention of amyloidosis, metabolic syndrome, and diabetics related diseases. The company was founded in 2002 and is headquartered in Laval, Canada. | - |
| Karen Eugeni | F | - |
Bellus Health (Innodia), Inc.
Bellus Health (Innodia), Inc. Pharmaceuticals: MajorHealth Technology Bellus Health (Innodia), Inc. manufactures biopharmaceutical products for the treatment and prevention of amyloidosis, metabolic syndrome, and diabetics related diseases. The company was founded in 2002 and is headquartered in Laval, Canada. | - |
| Serge Langford | M | - |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | - |
| John W. Gillard | M | - |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | - |
| Louisa Petropoulos | M | - |
Centre For Commercialization of Cancer Immunotherapy
Centre For Commercialization of Cancer Immunotherapy Centre For Commercialization of Cancer Immunotherapy provides solution for the development, translation, and commercialization of cancer immunotherapy and regenerative medicine. It offers clinical research unit, contract research organization, and innovation and commercialization unit services. The company was founded by Lambert Busque, Denis-Claude Roy and is headquartered in Montréal, Canada. | 8 anni |
| Yves Fouron | M | - |
Bellus Health (Innodia), Inc.
Bellus Health (Innodia), Inc. Pharmaceuticals: MajorHealth Technology Bellus Health (Innodia), Inc. manufactures biopharmaceutical products for the treatment and prevention of amyloidosis, metabolic syndrome, and diabetics related diseases. The company was founded in 2002 and is headquartered in Laval, Canada. | - |
| Joe Regan | M | 56 |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | - |
| Pavel Hamet | M | - |
Bellus Health (Innodia), Inc.
Bellus Health (Innodia), Inc. Pharmaceuticals: MajorHealth Technology Bellus Health (Innodia), Inc. manufactures biopharmaceutical products for the treatment and prevention of amyloidosis, metabolic syndrome, and diabetics related diseases. The company was founded in 2002 and is headquartered in Laval, Canada. | - |
| Trudie Resch | F | - |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | 17 anni |
| William Brock | M | - |
Centre For Commercialization of Cancer Immunotherapy
Centre For Commercialization of Cancer Immunotherapy Centre For Commercialization of Cancer Immunotherapy provides solution for the development, translation, and commercialization of cancer immunotherapy and regenerative medicine. It offers clinical research unit, contract research organization, and innovation and commercialization unit services. The company was founded by Lambert Busque, Denis-Claude Roy and is headquartered in Montréal, Canada. | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Charles Grubsztajn | M | - | 7 anni | |
| Richard Guay | M | 74 |
The Caisse de dépôt et placement du Québec
The Caisse de dépôt et placement du Québec Investment ManagersFinance The Caisse de dépôt et placement du Québec (CDPQ) is a government-owned institutional fund manager headquartered in Montréal, Canada. Founded in 1965, CDPQ manages the funds of several depositor groups primarily for public and parapublic pension and insurance plans which pay out benefits to more than two million Quebecers each year. | 14 anni |
| William Hugh Notman | M | 66 | 6 anni | |
| Charles Baum | M | 65 | 12 anni | |
| James Johnson | M | 67 |
AmpliPhi Biosciences Corp.
 AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 7 anni |
| Todd Simpson | M | 63 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 9 anni |
| Aki Georgacacos | M | - |
Advitech, Inc.
 Advitech, Inc. BiotechnologyHealth Technology Advitech Inc. is a health sciences and technology company, which develops, manufactures and marketes proprietary natural ingredients and formulations for oral and topical applications. Its products are based on three technological platforms: a superior multi-functional emulsification delivery system derived from plant seed oleosomes for formulation application in the topical cosmetic, OTC, Rx and natural personal care specialty ingredient markets, XP-828L for immune mediated inflammatory disorders and IM for anti-aging and wound healing. Advitech was founded in 1997 and is headquartered in Québec, Canada | 2 anni |
| Darrell J. Elliott | M | 77 | - | |
| Martin Godbout | M | - | 12 anni | |
| Michael Singer | M | 60 | 3 anni | |
| Joseph Walewicz | M | 55 | 3 anni | |
| David J. Poston | M | 61 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | - |
| Rodney Lappe | M | 69 | 7 anni | |
| Sean N. Karamchandani | M | - | - | |
| Donald G. Konantz | M | - | - | |
| Mattie Chinks | M | 74 | 4 anni | |
| Michel Lassonde | M | 82 | 3 anni | |
| Réjean Drouin | M | - |
Advitech, Inc.
Advitech, Inc. BiotechnologyHealth Technology Advitech Inc. is a health sciences and technology company, which develops, manufactures and marketes proprietary natural ingredients and formulations for oral and topical applications. Its products are based on three technological platforms: a superior multi-functional emulsification delivery system derived from plant seed oleosomes for formulation application in the topical cosmetic, OTC, Rx and natural personal care specialty ingredient markets, XP-828L for immune mediated inflammatory disorders and IM for anti-aging and wound healing. Advitech was founded in 1997 and is headquartered in Québec, Canada | 6 anni |
| Michael J. Stangel | M | - |
Advitech, Inc.
Advitech, Inc. BiotechnologyHealth Technology Advitech Inc. is a health sciences and technology company, which develops, manufactures and marketes proprietary natural ingredients and formulations for oral and topical applications. Its products are based on three technological platforms: a superior multi-functional emulsification delivery system derived from plant seed oleosomes for formulation application in the topical cosmetic, OTC, Rx and natural personal care specialty ingredient markets, XP-828L for immune mediated inflammatory disorders and IM for anti-aging and wound healing. Advitech was founded in 1997 and is headquartered in Québec, Canada | 2 anni |
| Patrice Hugo | M | 62 | 2 anni | |
| Preston Klassen | M | 55 | 6 anni | |
| Marc Olivier Perret | M | 65 | 7 anni | |
| Jim Scopa | M | 65 | 7 anni | |
| Daniel Ripley | M | 63 | 7 anni | |
| Jennifer Giottonini Cayer | F | - | 7 anni | |
| Dan Kisner | M | 77 | - | |
| Darrell Elliott | M | - | 2 anni | |
| Michael M. Mueller | M | - | - | |
| Marc-Andre Lebel | M | 69 | 2 anni | |
| Paul Klingenstein | M | 68 | 9 anni | |
| Michael Perry | M | 64 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 14 anni |
| Colin R. Mallet | M | 80 | 11 anni | |
| Guy Savard | M | 81 |
The Caisse de dépôt et placement du Québec
The Caisse de dépôt et placement du Québec Investment ManagersFinance The Caisse de dépôt et placement du Québec (CDPQ) is a government-owned institutional fund manager headquartered in Montréal, Canada. Founded in 1965, CDPQ manages the funds of several depositor groups primarily for public and parapublic pension and insurance plans which pay out benefits to more than two million Quebecers each year. | 5 anni |
| Henry Fuchs | M | 66 | 11 anni | |
| Christian Labbé | M | - |
Advitech, Inc.
Advitech, Inc. BiotechnologyHealth Technology Advitech Inc. is a health sciences and technology company, which develops, manufactures and marketes proprietary natural ingredients and formulations for oral and topical applications. Its products are based on three technological platforms: a superior multi-functional emulsification delivery system derived from plant seed oleosomes for formulation application in the topical cosmetic, OTC, Rx and natural personal care specialty ingredient markets, XP-828L for immune mediated inflammatory disorders and IM for anti-aging and wound healing. Advitech was founded in 1997 and is headquartered in Québec, Canada | 3 anni |
| François M. Grenier | M | - |
The Caisse de dépôt et placement du Québec
The Caisse de dépôt et placement du Québec Investment ManagersFinance The Caisse de dépôt et placement du Québec (CDPQ) is a government-owned institutional fund manager headquartered in Montréal, Canada. Founded in 1965, CDPQ manages the funds of several depositor groups primarily for public and parapublic pension and insurance plans which pay out benefits to more than two million Quebecers each year. | 17 anni |
| Richard O'Connor Whittall | M | 65 | 5 anni | |
| Jean-Luc Gravel | M | - |
The Caisse de dépôt et placement du Québec
The Caisse de dépôt et placement du Québec Investment ManagersFinance The Caisse de dépôt et placement du Québec (CDPQ) is a government-owned institutional fund manager headquartered in Montréal, Canada. Founded in 1965, CDPQ manages the funds of several depositor groups primarily for public and parapublic pension and insurance plans which pay out benefits to more than two million Quebecers each year. | 2 anni |
| Jacques Beaucham | M | - | - | |
| François Lagarde | M | - |
The Caisse de dépôt et placement du Québec
The Caisse de dépôt et placement du Québec Investment ManagersFinance The Caisse de dépôt et placement du Québec (CDPQ) is a government-owned institutional fund manager headquartered in Montréal, Canada. Founded in 1965, CDPQ manages the funds of several depositor groups primarily for public and parapublic pension and insurance plans which pay out benefits to more than two million Quebecers each year. | 3 anni |
| Pierre Sweeney | M | - | 2 anni | |
| Nicolas Gilles Chevalier | M | - |
The Caisse de dépôt et placement du Québec
The Caisse de dépôt et placement du Québec Investment ManagersFinance The Caisse de dépôt et placement du Québec (CDPQ) is a government-owned institutional fund manager headquartered in Montréal, Canada. Founded in 1965, CDPQ manages the funds of several depositor groups primarily for public and parapublic pension and insurance plans which pay out benefits to more than two million Quebecers each year. | - |
| Pierre Comtois | M | 82 | 4 anni | |
| Karen McTavish | F | - | 14 anni | |
| Luc Reny | M | - |
The Caisse de dépôt et placement du Québec
The Caisse de dépôt et placement du Québec Investment ManagersFinance The Caisse de dépôt et placement du Québec (CDPQ) is a government-owned institutional fund manager headquartered in Montréal, Canada. Founded in 1965, CDPQ manages the funds of several depositor groups primarily for public and parapublic pension and insurance plans which pay out benefits to more than two million Quebecers each year. | 6 anni |
| Luc Verville | M | - |
The Caisse de dépôt et placement du Québec
The Caisse de dépôt et placement du Québec Investment ManagersFinance The Caisse de dépôt et placement du Québec (CDPQ) is a government-owned institutional fund manager headquartered in Montréal, Canada. Founded in 1965, CDPQ manages the funds of several depositor groups primarily for public and parapublic pension and insurance plans which pay out benefits to more than two million Quebecers each year. | 16 anni |
| Pierre Bernard | M | - |
The Caisse de dépôt et placement du Québec
The Caisse de dépôt et placement du Québec Investment ManagersFinance The Caisse de dépôt et placement du Québec (CDPQ) is a government-owned institutional fund manager headquartered in Montréal, Canada. Founded in 1965, CDPQ manages the funds of several depositor groups primarily for public and parapublic pension and insurance plans which pay out benefits to more than two million Quebecers each year. | 12 anni |
| Susan Maria Da Sie | F | - |
The Caisse de dépôt et placement du Québec
The Caisse de dépôt et placement du Québec Investment ManagersFinance The Caisse de dépôt et placement du Québec (CDPQ) is a government-owned institutional fund manager headquartered in Montréal, Canada. Founded in 1965, CDPQ manages the funds of several depositor groups primarily for public and parapublic pension and insurance plans which pay out benefits to more than two million Quebecers each year. | 4 anni |
| Pierre Patry | M | - | 2 anni | |
| Aurel Wisse | M | - |
The Caisse de dépôt et placement du Québec
The Caisse de dépôt et placement du Québec Investment ManagersFinance The Caisse de dépôt et placement du Québec (CDPQ) is a government-owned institutional fund manager headquartered in Montréal, Canada. Founded in 1965, CDPQ manages the funds of several depositor groups primarily for public and parapublic pension and insurance plans which pay out benefits to more than two million Quebecers each year. | 26 anni |
| André Archimbaud | M | - | - | |
| Daniel Delorme | M | - | 5 anni | |
| Nafsika Dakou | M | - | - | |
| Alban D'Amours | M | 83 |
The Caisse de dépôt et placement du Québec
The Caisse de dépôt et placement du Québec Investment ManagersFinance The Caisse de dépôt et placement du Québec (CDPQ) is a government-owned institutional fund manager headquartered in Montréal, Canada. Founded in 1965, CDPQ manages the funds of several depositor groups primarily for public and parapublic pension and insurance plans which pay out benefits to more than two million Quebecers each year. | - |
| Achille E. Desmarais | M | 85 |
The Caisse de dépôt et placement du Québec
The Caisse de dépôt et placement du Québec Investment ManagersFinance The Caisse de dépôt et placement du Québec (CDPQ) is a government-owned institutional fund manager headquartered in Montréal, Canada. Founded in 1965, CDPQ manages the funds of several depositor groups primarily for public and parapublic pension and insurance plans which pay out benefits to more than two million Quebecers each year. | 14 anni |
| Margaret Mulligan | F | 65 | 1 anni | |
| Michel Drouin | M | - | - | |
| Fernand Perreault | M | 81 |
The Caisse de dépôt et placement du Québec
The Caisse de dépôt et placement du Québec Investment ManagersFinance The Caisse de dépôt et placement du Québec (CDPQ) is a government-owned institutional fund manager headquartered in Montréal, Canada. Founded in 1965, CDPQ manages the funds of several depositor groups primarily for public and parapublic pension and insurance plans which pay out benefits to more than two million Quebecers each year. | - |
| Adel Sarwat | M | - |
The Caisse de dépôt et placement du Québec
The Caisse de dépôt et placement du Québec Investment ManagersFinance The Caisse de dépôt et placement du Québec (CDPQ) is a government-owned institutional fund manager headquartered in Montréal, Canada. Founded in 1965, CDPQ manages the funds of several depositor groups primarily for public and parapublic pension and insurance plans which pay out benefits to more than two million Quebecers each year. | 13 anni |
| Chris Bryan | M | - |
The Caisse de dépôt et placement du Québec
The Caisse de dépôt et placement du Québec Investment ManagersFinance The Caisse de dépôt et placement du Québec (CDPQ) is a government-owned institutional fund manager headquartered in Montréal, Canada. Founded in 1965, CDPQ manages the funds of several depositor groups primarily for public and parapublic pension and insurance plans which pay out benefits to more than two million Quebecers each year. | 4 anni |
| Peter Thompson | M | 64 | - | |
| Raymond C. Egan | M | - | 10 anni | |
| Donald F. Corcoran | M | - | 14 anni | |
| Daniel A. Dupont | M | - |
The Caisse de dépôt et placement du Québec
The Caisse de dépôt et placement du Québec Investment ManagersFinance The Caisse de dépôt et placement du Québec (CDPQ) is a government-owned institutional fund manager headquartered in Montréal, Canada. Founded in 1965, CDPQ manages the funds of several depositor groups primarily for public and parapublic pension and insurance plans which pay out benefits to more than two million Quebecers each year. | 2 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Canada | 73 | 73.00% |
| Stati Uniti | 28 | 28.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Louis P. Lacasse
- Contatti personali
